Variable | N (%) or median (IQR) |
---|---|
CSF a | 123 (78.8) |
Protein level, g/L | 0.63 (0.39–1.13) |
Protein > 0.45 g/L | 85 (69.1) |
Cell count/µl | 1.0 (0–3) |
Cell count > 5/µl | 13 (10.6) |
Cytoalbuminological dissociation | 85 (69.1) |
Low FVC (< 1.5L or 20 mL/kg) at admission | 23/84 (27.4) |
MRI spine: root enhancement | 32/75 (42.7) |
MRI brain: cranial nerve enhancement | 2/76 (2.6) |
Electrophysiological subtypes as reportedb | 146 (93.6) |
AIDP | 55/146 (37.7) |
AMAN | 43/146 (29.5) |
AMSAN | 28/146 (19.2) |
Equivocal | 9/146 (6.2) |
Normal | 11/146 (7.5) |
Received GBS Therapyc | 151 (96.8) |
IVIg | 133/151 (88.1) |
PLEX | 18/151 (11.9) |
Repeated therapy d | 38/151 (25.2) |
IVIg–PLEX | 19/38 (50.0) |
IVIg–IVIg | 11/38 (28.9) |
PLEX–IVIg | 7/38 (18.4) |
PLEX–PLEX | 1/38 (2.6) |
Duration of hospitalization (N = 145, 93%) | 2.4 (1–8) weeks |
Outcome at follow-up | 97 (62.2%) |
Able to walk independently at < 6 months | 37/97 (38.1) |
Able to walk independently at 6 – 9 months | 11/97 (11.3) |
Able to walk independently at > 9 months | 32/97 (33.0) |
Able to walk with support at > 9 months | 10/97 (10.3) |
Unable to walk at > 9 months | 7/97 (7.2) |
Died (Septicemia) | 1/156 (0.64) |